Clene price to sales ratio CLNN

Market value divided by revenue over the last twelve months, since 2022.

Today, Oct 23, 2026: n/m; a sliver of sales
Last meaningful: 198×; Jan 2026
4-year median: 85.3×
4-year range: 44.8× to 199×
Peer median: 0.9×

Clene's price to sales ratio is not a meaningful number today: a multiple this high rests on a sliver of sales.

It was last meaningful in Jan 2026, at 198×.

On the days it had one over the last 4 years, its median was 85.3×, from 44.8× in Jul 2024 to 199× in Feb 2023.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	198×	198×	198×
2025	186×	60.8×	198×
2024	94.6×	44.8×	98.7×
2023	53.0×	51.9×	199×
2022	169×	157×	188×

Against its peers

Companies in Drug Manufacturers - General nearest Clene's size, closest first, today.

Company	Price to sales ratio
CLNNClene	n/m
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
NATRNatures Sunshine Products	0.4×
ARVNArvinas	1.5×
Peer median	0.9×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Clene

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.